NCT06465732View on ClinicalTrials.gov

Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

July 31, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

the active comparator arm receive dupilumab only

DRUG

Tofacitinib

the experimental arm receive dupilumab plus tofacitinib.

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER